Skip to main content

First-Line Treatment Strategies for Elderly Patients with Metastatic Colorectal Cancer

Drugs & Aging volume 24, pages 223–238 (2007)Cite this article

Abstract

Colorectal cancer ranks third in incidence in both men and women after lung, breast and prostate cancer. The prevalence of colorectal cancer increases significantly with age, with 40% of patients in Europe being >75 years of age at the time of initial diagnosis. Furthermore, the number of elderly patients with colorectal cancer is expected to increase significantly over the next two decades.

Treatment of advanced colorectal cancer has evolved dramatically over the last decade. Advances in surgery and chemotherapy are effective in prolonging time to disease progression and survival in patients with advanced colorectal cancer. For >40 years, fluorouracil has been the mainstay of chemotherapy for advanced colorectal cancer. Recently, however, newer cytotoxic chemotherapies and biological agents effective against colorectal cancer have been shown to improve overall survival in metastatic disease. Thus, a patient with metastatic colorectal cancer today has an expected median survival of 20 months compared with 10 months only a few years ago.

There is evidence that elderly individuals derive as much survival benefit from standard chemotherapy approaches in metastatic colorectal cancer as younger patients. Unfortunately, most older patients who might benefit from chemotherapy are not offered this treatment, and the fraction who are not offered it increases with increasing age. Treatment decisions should not be made on the basis of age. Rather, they should be based on functional status, the presence of co-morbidities, and consideration of drug-specific toxicities that can be aggravated in older individuals because of decreased functional reserve.

Although the elderly have been under-represented in clinical trials, studies also support the effectiveness of combination chemotherapy in elderly patients with advanced colorectal cancer.

This article reviews current optimal first-line treatment strategies for elderly patients with metastatic colorectal cancer.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Table II
Table III

References

  1. Matasar MJ, Sundararajan V, Grann VR, et al. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy. Drugs Aging 2004; 2(2): 113–33

    Article  Google Scholar 

  2. Vercelli M, Quaglia A, Casella C, et al. Relative survival in elderly cancer patients in Europe. Eur J Cancer 1998; 34: 2264–70

    PubMed  Article  CAS  Google Scholar 

  3. Denduluriand N, Ershler WB. Aging biology and cancer. Semin Oncol 2004; 31: 137–48

    Article  Google Scholar 

  4. Lichtman SM. Management of advanced colorectal cancer in older patients. Oncology 2005 Apr; 19(5): 597–602

    PubMed  Google Scholar 

  5. Muss HB, Longo DL. Introduction: cancer in the elderly. Semin Oncol 2004; 31: 125–7

    Article  Google Scholar 

  6. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091–7

    PubMed  Article  CAS  Google Scholar 

  7. Lichtmann SM. Guidelines for the treatment of elderly cancer patients. Cancer Control 2003; 10(6): 445–53

    Google Scholar 

  8. Monfardini S, Sorio R, Boes GH, et al. Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies. Cancer 1995; 76: 333–8

    PubMed  Article  CAS  Google Scholar 

  9. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061–7

    PubMed  Article  CAS  Google Scholar 

  10. Kemeny M, Muss HB, Kornblith AB, et al. Barriers to participation of older women with breast cancer in clinical trials [abstract]. Prog Proc Am Soc Clin Oncol 2000; 19: 602a

    Google Scholar 

  11. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994; 74Suppl. 7: 2208–14

    PubMed  Article  CAS  Google Scholar 

  12. Muss HB. Older age: not a barrier to cancer treatment. N Engl J Med 2001; 345(15): 1128–9

    Article  Google Scholar 

  13. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998; 82: 2123–34

    PubMed  Article  CAS  Google Scholar 

  14. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16(4): 1582–7

    PubMed  CAS  Google Scholar 

  15. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476–87

    PubMed  Article  CAS  Google Scholar 

  16. Simmonds PD, Best L, George S, et al. Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 2000; 356: 968–74

    Article  Google Scholar 

  17. Puig-La Calle J Jr, Quayle J, Thaler HT, et al. Favorable short-term and long-term outcome after elective radical rectal cancer resection in patients 75 years of age or older. Dis Colon Rectum 2000; 43(12): 1704–9

    PubMed  Article  Google Scholar 

  18. Zingmond D, Maggard M, O’Connell J, et al. What predicts serious complications in colorectal cancer resection? Am Surg 2003; 69(11): 969–74

    PubMed  Google Scholar 

  19. Temple LK, Hsieh L, Wong WD, et al. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 2004 Sep 1; 22(17): 3475–84

    PubMed  Article  Google Scholar 

  20. Goyle S, Maraveyas A. Chemotherapy for colorectal cancer. Dig Surg 2005; 22: 401–14

    PubMed  Article  CAS  Google Scholar 

  21. The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766–75

    Article  Google Scholar 

  22. Best L, Simmonds P, Baughan C, et al. Palliative chemotherapy for advanced or metastatic colorectal cancer. In: Colorectal Meta-analysis Collaboration. The Cochrane Library. Issue 2. Chichester: John Wiley & Sons, Ltd, 2000: CD001545

    Google Scholar 

  23. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a mul-ticentre randomised trial. Lancet 2000; 355: 1041–7

    PubMed  Article  CAS  Google Scholar 

  24. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47

    PubMed  Google Scholar 

  25. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209–14

    PubMed  Article  CAS  Google Scholar 

  26. Milburn Jessup J, Stewart A, Greene FL. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age and differentiation. JAMA 2005; 294: 2703–11

    PubMed  Article  Google Scholar 

  27. Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17(8): 2412–8

    PubMed  CAS  Google Scholar 

  28. Köhne CH, Cunningham D, di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308–17

    PubMed  Article  Google Scholar 

  29. Mahoney T, Kuo Y-H, Topilow A, et al. Stage III colon cancer: why adjuvant treatment is not offered to elderly patients. Arch Surg 2000; 135: 182–5

    PubMed  Article  CAS  Google Scholar 

  30. Schrag D, Cramer L, Bach P, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93: 850–7

    PubMed  Article  CAS  Google Scholar 

  31. Sundararajan V, Grann V, Neugut A. Population based variation in the use of chemotherapy for colorectal cancer in the elderly [abstract]. Proc Am Soc Clin Oncol 1999; 18: A1598

    Google Scholar 

  32. Lichtman SM. Chemotherapy in the elderly. Semin Oncol 2004; 31(2): 160–74

    PubMed  Article  CAS  Google Scholar 

  33. Wasil T, Lichtman SM. Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. Oncologist 2005; 10: 602–12

    PubMed  Article  Google Scholar 

  34. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cyto-chrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61: 331–9

    PubMed  Article  CAS  Google Scholar 

  35. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27(1): 23–44

    PubMed  Article  CAS  Google Scholar 

  36. Takimoto CH, Remick SC, Sharma S, et al. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 2003; 30: 20–5

    PubMed  Article  CAS  Google Scholar 

  37. Jefford M, Zalcberg J. Recent advances in the systemic therapy of metastatic colorectal cancer. Am J Cancer 2005; 4(1): 15–34

    Article  CAS  Google Scholar 

  38. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004; 40(7): 939–50

    PubMed  Article  Google Scholar 

  39. Li HX, Zh S, Zhang YH, et al. Expressions of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase in breast cancer and their correlations with prognosis. Chinese J Oncol 2004; 26(11): 669–72

    CAS  Google Scholar 

  40. Li H, Suo Z, Zhang Y, et al. The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas. Histol Histopathol 2004; 19(1): 129–36

    PubMed  CAS  Google Scholar 

  41. The Meta-Analysis Group in Cancer. Colorectal Cancer Meta-Analysis Project: efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–8

    Google Scholar 

  42. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19(8): 2282–92

    PubMed  CAS  Google Scholar 

  43. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19(21): 4097–106

    PubMed  Google Scholar 

  44. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15: 1330–8

    PubMed  Article  CAS  Google Scholar 

  45. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006; 24(15): 2368–75

    PubMed  Article  CAS  Google Scholar 

  46. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group Study. J Clin Oncol 2005; 23: 3104–11

    PubMed  Article  CAS  Google Scholar 

  47. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566–57

    PubMed  Article  CAS  Google Scholar 

  48. Golfinopoulos V, Pentheroudakis G, Pavlidis N. Treatment of colorectal cancer in the elderly: a review of the literature. Cancer Treat Rev 2006; 32(1): 1–8

    PubMed  Article  Google Scholar 

  49. Rougier P, van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407–12

    PubMed  Article  CAS  Google Scholar 

  50. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–8

    PubMed  Article  CAS  Google Scholar 

  51. Köhne CH, Van Cutsem E, Wils JA, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856–65

    PubMed  Article  Google Scholar 

  52. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905–14

    PubMed  Article  CAS  Google Scholar 

  53. Rothenberg M, Cox J, DeVore R, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85: 786–95

    PubMed  Article  CAS  Google Scholar 

  54. Sastre J, Marcuello E, Masutti B, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005 May 20; 23(15): 3545–51

    PubMed  Article  CAS  Google Scholar 

  55. Mitry E, Douillard JY, van Cutsem E, et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004; 15: 1013–7

    PubMed  Article  CAS  Google Scholar 

  56. Chau I, Norman AR, Cunningham D, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004; 91: 1453–8

    PubMed  Article  CAS  Google Scholar 

  57. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004 Oct; 5(7): 835–43

    PubMed  Article  CAS  Google Scholar 

  58. de Jong FA, Kehrer DFS, Mathijssen RHJ, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 2006; 11(8): 944–54

    PubMed  Article  Google Scholar 

  59. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998; 16: 2739–44

    PubMed  CAS  Google Scholar 

  60. Raymond E, Emanuel D, Rostagi R, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053–71

    PubMed  Article  CAS  Google Scholar 

  61. Giacchetti S, Perpoint B, Zidane R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136–47

    PubMed  CAS  Google Scholar 

  62. Exquis B, Aapro M, Kohler S. Oxaliplatin (with 5FU and leucovorin) in patients above age 70 (elderly) suffering from metastatic colorectal cancer: an observational study [abstract 8042]. Proc Am Soc Clin Oncol 2004; 23: 735

    Google Scholar 

  63. Cassidy J, Taberno J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084–91

    PubMed  Article  CAS  Google Scholar 

  64. Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006; 94(7): 969–75

    PubMed  Article  CAS  Google Scholar 

  65. Cornelia P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal cancer: final results of the Southern Italy Cooperative Oncology Group (SICOG) trial 0108. Cancer 2005; 104: 282–9

    Article  Google Scholar 

  66. Sargent DJ, Goldberg RM, Bleiberg H, et al. A pooled safety and efficacy analysis of the FOLFOX4 regimen (bimonthly oxaliplatin plus fluorouracil/leucovorin) in elderly compared to younger patients with colorectal cancer [abstract no. 228]. In: Program and abstracts of the 2006 Gastrointestinal Cancers Symposium; 2006 Jan 26–28; San Francisco

  67. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71: 2454–60

    PubMed  Article  CAS  Google Scholar 

  68. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004 Jul 22; 351(4): 337–45

    PubMed  Article  CAS  Google Scholar 

  69. Saltz L, Kies M, Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract]. Prog Proc Am Soc Clin Oncol 2003; 22: 204a

    Google Scholar 

  70. Kabbinavar FF, Schulz J, McCleod M, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11 [abstract]. Proc Am Soc Clin Oncol 2004; 23: 3516

    Google Scholar 

  71. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335–42

    PubMed  Article  CAS  Google Scholar 

  72. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 Jan 1; 21(1): 60–5

    PubMed  Article  CAS  Google Scholar 

  73. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 Jul 31; 349(5): 427–34

    PubMed  Article  CAS  Google Scholar 

  74. Maughan T. Fluorouracil, oxaliplatin, CPT-11, use and sequencing, in advanced colorectal cancer: the UK MRC FOCUS (CR08) Trial [abstract no. 165]. In: GI Cancers Symposium; 2005 Jan 27–29; Hollywood (FL)

  75. Mattioli R, Lippe P, Recchia F, et al. Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion. Anticancer Res 2001 Jan-Feb; 21(1A): 489–92

    PubMed  CAS  Google Scholar 

  76. Enzinger PC, Mayer RJ. Gastrointestinal cancer in older patients. Semin Oncol 2004; 31(2): 206–19

    PubMed  Article  Google Scholar 

  77. Mattioli R, Massacesi C, Recchia F, et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005; 16(7): 1147–51

    PubMed  Article  CAS  Google Scholar 

  78. Hamermann D. Toward an understanding of frailty. Ann Intern Med 1999; 130: 945–50

    Google Scholar 

  79. Carreca I, Balducci L. Oral chemotherapy for the older patient with cancer. Am J Cancer 2002; 1(2): 101–8

    Article  CAS  Google Scholar 

  80. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83

    PubMed  Article  CAS  Google Scholar 

  81. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998 Apr; 16(4): 1582–7

    PubMed  CAS  Google Scholar 

  82. Balducci L, Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol 2000; 35(3): 147–54

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Affiliations

  1. Department of Internal Medicine, Catharina Hospital, Michelangelolaan 2, Eindhoven, 5623 EJ, The Netherlands

    Hielke J. Meulenbeld & Geert-Jan Creemers

Authors
  1. Hielke J. Meulenbeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geert-Jan Creemers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hielke J. Meulenbeld.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Meulenbeld, H.J., Creemers, GJ. First-Line Treatment Strategies for Elderly Patients with Metastatic Colorectal Cancer. Drugs Aging 24, 223–238 (2007). https://doi.org/10.2165/00002512-200724030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200724030-00004

Keywords

  • Colorectal Cancer
  • Bevacizumab
  • Fluorouracil
  • Irinotecan
  • Oxaliplatin